+86-531-88916568
Fusen Pharmaceutical (01652. HK) joint venture with Jiangxi Kangde was granted the exclusive license to develop, produce and sell Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection
Home » News » Fusen Pharmaceutical (01652. HK) joint venture with Jiangxi Kangde was granted the exclusive license to develop, produce and sell Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection

Fusen Pharmaceutical (01652. HK) joint venture with Jiangxi Kangde was granted the exclusive license to develop, produce and sell Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection

Views:0     Author:Site Editor     Publish Time: 2021-02-15      Origin:Gelonghui

Fushen Pharmaceutical (01652. HK) announced that on February 10, 2021, Jiangxi Yongfeng Kangde Pharmaceutical Co., Ltd(Jiangxi Kangdeas the licensee), a joint venture of the company, entered into a license agreement with Bica Biotechnology (Guangzhou) Co., Ltd. (Bica as the licensee), an independent third party. Accordingly, (including) Jiangxi Kangde and Bica will enter into a license agreement with Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer), Jiangxi Kangde has been granted the exclusive license (including) to carry out research and development activities, manufacture and sell Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection in the licensed area.


Bica agrees to grant Jiangxi Kangdean exclusive license to conduct R & D activities, manufacture and sell Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection in China. Jiangxi Kangde will be responsible for the follow-up clinical research, drug registration, marketing and promotion of docetaxel injection. It will be granted the commercial right of all indications of Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection in the license area. Jiangxi Kangde and bica will jointly supervise and coordinate the research and development of Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer)injection, and continue to promote the drug registration approval issued by the State Drug Administration of China. According to the license agreement, Jiangxi Kangde shall (I) pay advance payment to bicar after the execution of the license agreement; (II) pay milestone payment to bicar depending on the research and development stage of docetaxel injection; and (III) pay license fee to bicar for the sale of docetaxel injection. 

PRODUCT CATEGORY

QUICK LINKS

CONTACT INFORMATION

Tel: +86-531-88916568
 Mail: enquiry@cydextrin.com
​​​​​​​ Address: Boxing Economic Development Zone, Binzhou, Shandong, China.

FREE CONSULTATION

Contact us
© 2020 Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. All rights reserved. Sitemap